|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
|
31182803 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
|
31018569 |
2019 |
|
Breast Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
|
31182803 |
2019 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
|
31018569 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
NET dose-dependently increased BC cell viability and this effect was accompanied by increased expression of PGRMC1.
|
29907248 |
2018 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
NET dose-dependently increased BC cell viability and this effect was accompanied by increased expression of PGRMC1.
|
29907248 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
CTD_human |
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.
|
16583263 |
2006 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.
|
16583263 |
2006 |
|
Heart Failure, Diastolic
|
0.300 |
Biomarker
|
disease |
CTD_human |
In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.
|
29556499 |
2018 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.
|
16583263 |
2006 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.
|
16583263 |
2006 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.
|
16583263 |
2006 |
|
Chylothorax, congenital
|
0.200 |
Biomarker
|
disease |
MGD |
Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1.
|
11566878 |
2001 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy has limited therapeutic benefit.
|
31846429 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor expression of neither ELK3 nor ELK4 was associated with disease-free survival (DFS).
|
31794091 |
2020 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SATB2 is frequently and strongly expressed by lower GI tract NETs; we have adopted it as our rectal NET marker.
|
31233624 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NET-U represents an aggressive form of uterine malignancy.
|
31074241 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no relationship between C. albicans MLST profiles and their geographic distribution, cancer type and SAP2 gene expression.
|
31630914 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We present a case of a 58-year-old adult patient with dyspeptic symptoms who was incidentally diagnosed with triple malignancy (pheochromocytoma, multiple GISTs of small intestine and an ampullary NET) as a first manifestation of NF1.
|
31301733 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In MDA-MB-231 breast cancer cells, knockdown of RSK2 or ELK3 suppressed cell proliferation with accumulation at the G1 cell cycle phase, resulting in inhibition of foci formation and anchorage-independent cancer colony growth in soft agar.
|
31018569 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One of the main obstacles to improve current treatments is represented by the impermeability of the blood vessels residing within nervous tissue as well as of the new vascular net generating from the tumor, commonly referred to as blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), respectively.
|
31137689 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These biomarkers include (1) peptides and growth factors; (2) DNA and RNA markers based on genomics analysis, for example, the so-called NET test, which has been developed for analyzing gene transcripts in circulating blood; (3) circulating tumor/endothelial/progenitor cells or cell-free tumor DNA, which represent minimally invasive methods that would provide additional information for monitoring treatment response and (4) improved imaging techniques with novel radiolabeled somatostatin analogs or peptides.
|
30615596 |
2019 |